Tact.ai, founded in Silicon Valley, aims to revolutionize customer engagement in the life sciences sector through its AI-powered, human-friendly software. The company's core mission is to empower field teams to interact with customers in innovative ways, enhancing overall outcomes. Tact.ai offers an engagement platform specifically designed for life science organizations, focusing on meaningful customer interactions and improved engagement strategies.
Notable investors in Tact.ai include Microsoft's venture fund M12, Salesforce Ventures, Novartis, and Lilly. These affiliations underscore the company's strong backing from leading firms in venture capital, technology, and healthcare. Tact.ai has achieved significant milestones in transforming customer engagement practices within the life sciences industry, making a substantial impact by enabling more effective and personalized interactions between field teams and their clients.
